Document Detail

Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
MedLine Citation:
PMID:  15757817     Owner:  NLM     Status:  MEDLINE    
This is an open study to compare the cure rate of cutaneous leishmaniasis caused by L. major and treated with either paromomycin sulfate or intralesional injection of meglumine antimoniate. Sixty parasitologically proven cases with 1-3 lesions were included and divided randomly into two equal groups; one group received 1 ml of meglumine antimonate intradermally every other day for 20 days, the other group received the ointment containing 15% parmomycin sulfate in urea twice daily for 20 days. The patients were clinically evaluated at 1 and 6 weeks after treatment was completed. The results of clinical evaluation at 1 week after treatment completed showed a cure rate of 18 out of 27 (66%) in the meglumine antimonate injected group and 20 out of 29 (68%) in the paromomycin sulfate treated group. The chi square test was used to compare the cure rate between the two groups and showed no significant difference (p = 0.85).
Babak Shazad; Babak Abbaszadeh; Ali Khamesipour
Related Documents :
8016257 - Botulinum toxin a for hyperkinetic facial lines: results of a double-blind, placebo-con...
8467837 - Effectiveness of botulinum toxin in the treatment of spasmodic torticollis.
8348217 - Erectile dysfunction in men under 40: etiology and treatment choice.
3884297 - A randomized trial of photocoagulation or injection sclerotherapy for the treatment of ...
23250097 - Spatial analysis of deaths due to traffic accidents, before and after the brazilian dri...
3115287 - Efficacy of antiprostaglandin therapy in vernal conjunctivitis.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  European journal of dermatology : EJD     Volume:  15     ISSN:  1167-1122     ISO Abbreviation:  Eur J Dermatol     Publication Date:    2005 Mar-Apr
Date Detail:
Created Date:  2005-03-10     Completed Date:  2005-06-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9206420     Medline TA:  Eur J Dermatol     Country:  France    
Other Details:
Languages:  eng     Pagination:  85-7     Citation Subset:  IM    
Internal Medicine Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Anti-Bacterial Agents / therapeutic use*
Antiprotozoal Agents / administration & dosage,  therapeutic use*
Injections, Intralesional
Leishmania major / pathogenicity*
Leishmaniasis, Cutaneous / drug therapy*,  parasitology
Meglumine / administration & dosage,  therapeutic use*
Organometallic Compounds / administration & dosage,  therapeutic use*
Paromomycin / administration & dosage,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Antiprotozoal Agents; 0/Organometallic Compounds; 133-51-7/meglumine antimoniate; 6284-40-8/Meglumine; 7542-37-2/Paromomycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Desmosome-binding antibody KM48 recognises an extracellular antigen different from desmosomal cadher...
Next Document:  Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo.